Direxion Daily S&P Biotech Bear 3X ETF
LABD
12 hedge funds and large institutions have $9.23M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
168% more call options, than puts
Call options by funds: $1.68M | Put options by funds: $628K
10% more capital invested
Capital invested by funds: $8.41M → $9.23M (+$817K)
0.7% more ownership
Funds ownership: 7.28% → 7.98% (+0.7%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$2.5M |
| 2 |
Morgan Stanley
New York
|
+$2.14M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.3M |
| 4 |
VF
Virtu Financial
New York
|
+$1.14M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$5.69M |
| 2 |
Jane Street
New York
|
-$368K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$269K |
| 4 |
CT
CMT Trading
Chicago,
Illinois
|
-$9.96K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$9.96K |
LABD Hedge Fund Activity: Q4 2017 in Review
12 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q4 2017, worth a combined $9.23M — up 9.7% from $8.41M a quarter earlier.
Fund positioning in LABD was balanced in Q4 2017: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was SG Americas Securities, adding an estimated $2.5M. The largest seller was Citigroup, cutting an estimated $5.69M.
- 12 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $9.23M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q4 2017, up 9.7% quarter-over-quarter.
- 2 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q4 2017 and 2 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q4 2017 was SG Americas Securities, an estimated $2.5M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q4 2017 was Citigroup, an estimated $5.69M sold.
Based on aggregated 13F filings for Q4 2017.